270 related articles for article (PubMed ID: 26399966)
1. Discrete partitioning of HIV-1 Env forms revealed by viral capture.
Stieh DJ; King DF; Klein K; Aldon Y; McKay PF; Shattock RJ
Retrovirology; 2015 Sep; 12():81. PubMed ID: 26399966
[TBL] [Abstract][Full Text] [Related]
2. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.
Moore PL; Crooks ET; Porter L; Zhu P; Cayanan CS; Grise H; Corcoran P; Zwick MB; Franti M; Morris L; Roux KH; Burton DR; Binley JM
J Virol; 2006 Mar; 80(5):2515-28. PubMed ID: 16474158
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
Chen J; Kovacs JM; Peng H; Rits-Volloch S; Lu J; Park D; Zablowsky E; Seaman MS; Chen B
Science; 2015 Jul; 349(6244):191-5. PubMed ID: 26113642
[TBL] [Abstract][Full Text] [Related]
4. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.
Lai RP; Yan J; Heeney J; McClure MO; Göttlinger H; Luban J; Pizzato M
PLoS Pathog; 2011 Dec; 7(12):e1002442. PubMed ID: 22194689
[TBL] [Abstract][Full Text] [Related]
5. Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions.
Zhang S; Nguyen HT; Ding H; Wang J; Zou S; Liu L; Guha D; Gabuzda D; Ho DD; Kappes JC; Sodroski J
J Virol; 2021 Jan; 95(3):. PubMed ID: 33148792
[TBL] [Abstract][Full Text] [Related]
6. Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.
Blay WM; Kasprzyk T; Misher L; Richardson BA; Haigwood NL
J Virol; 2007 Dec; 81(23):13037-49. PubMed ID: 17855534
[TBL] [Abstract][Full Text] [Related]
7. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.
Leaman DP; Kinkead H; Zwick MB
J Virol; 2010 Apr; 84(7):3382-95. PubMed ID: 20089658
[TBL] [Abstract][Full Text] [Related]
8. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
9. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
[TBL] [Abstract][Full Text] [Related]
10. Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure.
Ray K; Mengistu M; Orlandi C; Pazgier M; Lewis GK; DeVico AL
Front Immunol; 2019; 10():1512. PubMed ID: 31338095
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41.
Burrer R; Haessig-Einius S; Aubertin AM; Moog C
Virology; 2005 Mar; 333(1):102-13. PubMed ID: 15708596
[TBL] [Abstract][Full Text] [Related]
12. HIV. The modern era of HIV-1 vaccine development.
Mascola JR
Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
[No Abstract] [Full Text] [Related]
13. Antigenic properties of the HIV envelope on virions in solution.
Ray K; Mengistu M; Yu L; Lewis GK; Lakowicz JR; DeVico AL
J Virol; 2014 Feb; 88(3):1795-808. PubMed ID: 24284318
[TBL] [Abstract][Full Text] [Related]
14. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.
Parren PW; Gauduin MC; Koup RA; Poignard P; Fisicaro P; Burton DR; Sattentau QJ
Immunol Lett; 1997 Jun; 57(1-3):105-12. PubMed ID: 9232434
[TBL] [Abstract][Full Text] [Related]
15. Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".
Parren PW; Gauduin MC; Koup RA; Poignard P; Sattentau QJ; Fisicaro P; Burton DR
Immunol Lett; 1997 Jul; 58(2):125-32. PubMed ID: 9271324
[TBL] [Abstract][Full Text] [Related]
16. Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike.
Cai Y; Karaca-Griffin S; Chen J; Tian S; Fredette N; Linton CE; Rits-Volloch S; Lu J; Wagh K; Theiler J; Korber B; Seaman MS; Harrison SC; Carfi A; Chen B
Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4477-4482. PubMed ID: 28396421
[TBL] [Abstract][Full Text] [Related]
17. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes.
McKenna PM; Pomerantz RJ; Dietzschold B; McGettigan JP; Schnell MJ
J Virol; 2003 Dec; 77(23):12782-94. PubMed ID: 14610200
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells.
Wang Q; Zhang S; Nguyen HT; Sodroski J
J Virol; 2024 Feb; 98(2):e0159423. PubMed ID: 38289101
[TBL] [Abstract][Full Text] [Related]
19. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.
Dey AK; David KB; Ray N; Ketas TJ; Klasse PJ; Doms RW; Moore JP
Virology; 2008 Mar; 372(1):187-200. PubMed ID: 18031785
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
Trott M; Weiβ S; Antoni S; Koch J; von Briesen H; Hust M; Dietrich U
PLoS One; 2014; 9(5):e97478. PubMed ID: 24828352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
